GlassScriptPhysician profile
Brian M Slomovitz
NPI 1306885512
$518,925.73
in general payments reported to CMS, 2019-2025
69 companies · $128K in 2025
The $128K reported for 2025 was more than what 99% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $39K · 2021: $57K · 2022: $68K · 2023: $94K · 2024: $93K · 2025: $128K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $200K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Travel and Lodging: $21K · Food and Beverage: $11K · Honoraria: $5,565 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,445 · Grant: $597 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $199,685.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,610.00 |
| Travel and Lodging | $20,923.48 |
| Food and Beverage | $11,132.61 |
| Honoraria | $5,565.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,445.00 |
| Grant | $596.93 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $133,566.23 | 2019-2025 | Keytruda, Lenvima, Lynparza |
| Seagen INC. | $71,219.04 | 2021-2023 | Tivdak, Padcev, Adcetris |
| Astrazeneca Pharmaceuticals LP | $69,288.83 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Eisai INC. | $20,918.88 | 2019-2025 | |
| Tesaro, INC. | $18,563.54 | 2019 | |
| Incyte Corporation | $18,386.41 | 2021-2025 | Monjuvi, Jakafi, Pemazyre |
| Genmab U.S., INC. | $18,368.36 | 2023-2024 | Epkinly |
| Astrazeneca Uk Limited | $18,042.90 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Aadi Bioscience, INC. | $17,524.18 | 2022-2025 | Fyarro, Fyarro |
| Karyopharm Therapeutics INC. | $17,010.05 | 2023-2024 | Xpovio |
| Daiichi Sankyo INC. | $15,751.22 | 2019-2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $13,737.07 | 2020-2025 | |
| Abbvie INC. | $13,316.09 | 2019-2025 | |
| Novocure Gmbh | $7,965.00 | 2022-2023 | |
| Corcept Therapeutics | $7,635.98 | 2025 | Korlym |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $7,163.13 | 2021-2024 | |
| Regeneron Pharmaceuticals, INC. | $5,965.88 | 2022-2023 | |
| Clovis Oncology, INC. | $5,408.29 | 2019-2022 | |
| Biontech Se | $4,813.51 | 2023-2025 | |
| Eli Lilly and Company | $4,200.00 | 2021 | |
| Immunocore Limited | $3,684.72 | 2023 | Kimmtrak |
| Myriad Genetic Laboratories, INC. | $3,480.73 | 2020-2024 | Precisetumor, Myrisk |
| Gilead Sciences, INC. | $3,325.34 | 2023 | |
| Beone Medicines USA, INC. | $2,506.31 | 2025 | Tevimbra, Brukinsa |
| F. Hoffmann-La Roche Ag | $2,370.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $2,311.57 | 2021-2025 | |
| Novocure INC. | $2,240.17 | 2019-2022 | |
| Pfizer INC. | $2,008.32 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $1,800.00 | 2021 | |
| Genentech, INC. | $1,719.08 | 2022-2023 | |
| Immunogen, INC. | $1,662.34 | 2023-2024 | Elahere, Elahere |
| Janssen Biotech, INC. | $393.70 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Aveo Pharmaceuticals, INC. | $276.95 | 2021-2025 | Fotivda |
| Intuitive Surgical, INC. | $236.08 | 2021 | |
| Genentech USA, INC. | $174.95 | 2019-2025 | Phesgo, Tecentriq Hybreza, Alecensa |
| Pharmacosmos Therapeutics INC. | $174.34 | 2023-2025 | Monoferric, Cosela |
| Exelixis INC. | $157.84 | 2022-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $157.24 | 2023-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Deciphera Pharmaceuticals INC. | $140.75 | 2022-2025 | Qinlock, Tgct |
| Adaptive Biotechnologies Corporation | $127.62 | 2022-2025 | Clonoseq |
| Servier Pharmaceuticals LLC | $119.44 | 2022-2025 | |
| Lilly USA, LLC | $103.34 | 2022-2025 | Verzenio, Retevmo, Jaypirca |
| Astellas Pharma US INC | $91.30 | 2022-2024 | Padcev |
| Caris Mpi, INC. | $85.25 | 2025 | Mi Cancer Seek |
| Pharmacyclics LLC, An Abbvie Company | $81.64 | 2022-2023 | Epkinly, Imbruvica |
| Emd Serono, INC. | $66.27 | 2024-2025 | |
| Genzyme Corporation | $50.07 | 2024-2025 | |
| Stemline Therapeutics INC. | $44.89 | 2024-2025 | Orserdu |
| Agios Pharmaceuticals, INC. | $43.67 | 2025 | Pyrukynd |
| G1 Therapeutics, INC. | $42.15 | 2023 | Cosela |
| Taiho Oncology, INC. | $40.18 | 2023-2024 | |
| Sobi, INC | $38.84 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $34.77 | 2024 | Ultomiris |
| Celgene Corporation | $33.93 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $29.39 | 2025 | Onivyde |
| Amgen INC. | $27.55 | 2022-2023 | Kyprolis, Blincyto |
| American Regent | $24.93 | 2024 | Injectafer |
| Geron Corporation | $24.82 | 2025 | Rytelo |
| Mirati Therapeutics, INC. | $22.58 | 2024 | Krazati |
| Kyowa Kirin, INC. | $22.40 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.75 | 2024 | |
| Tersera Therapeutics LLC | $17.34 | 2025 | Zoladex |
| Recordati_rare_diseases_inc. | $14.57 | 2024 | Sylvant |
| Tempus Ai, INC | $14.39 | 2024 | Xt Cdx |
| Tolmar, INC. | $14.26 | 2025 | Rubraca |
| Pharmaand Gmbh | $14.26 | 2025 | Rubraca |
| Janssen Pharmaceuticals, INC | $12.11 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$780.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Slomovitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.